These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27983793)

  • 1. Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies.
    Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K
    ACS Chem Neurosci; 2017 Apr; 8(4):860-865. PubMed ID: 27983793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin-Derived Nanolipoidal Carriers for Brain Delivery of Dimethyl Fumarate: A Novel Approach with Preclinical Evidence.
    Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K
    ACS Chem Neurosci; 2017 Jun; 8(6):1390-1396. PubMed ID: 28157295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stearic acid based, systematically designed oral lipid nanoparticles for enhanced brain delivery of dimethyl fumarate.
    Kumar P; Sharma G; Kumar R; Malik R; Singh B; Katare OP; Raza K
    Nanomedicine (Lond); 2017 Dec; 12(23):2607-2621. PubMed ID: 29094640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises of a biocompatible nanocarrier in improved brain delivery of quercetin: Biochemical, pharmacokinetic and biodistribution evidences.
    Kumar P; Sharma G; Kumar R; Singh B; Malik R; Katare OP; Raza K
    Int J Pharm; 2016 Dec; 515(1-2):307-314. PubMed ID: 27756627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Explorative Assessment of Dimethyl Fumarate-Based Biocompatible Nanolipoidal Carriers for the Management of Multiple Sclerosis.
    Kumar P; Sharma G; Gupta V; Kaur R; Thakur K; Malik R; Kumar A; Kaushal N; Raza K
    ACS Chem Neurosci; 2018 May; 9(5):1152-1158. PubMed ID: 29357233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
    Li H; Chen M; Su Z; Sun M; Ping Q
    Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics.
    Wavikar P; Pai R; Vavia P
    J Pharm Sci; 2017 Dec; 106(12):3613-3622. PubMed ID: 28923321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
    Salunkhe SS; Bhatia NM; Bhatia MS
    Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R; Li YZ; Chen C; Cao YN; Yu MM; Xu L; He B; Jie X; Shen WW; Wang YN; van Dongen MA; Liu GQ; Banaszak Holl MM; Zhang Q; Ke X
    J Control Release; 2015 Jul; 210():160-8. PubMed ID: 26003044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS).
    Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S
    Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promises of Lipid-Based Nanocarriers for Delivery of Dimethyl Fumarate to Multiple Sclerosis Brain.
    Subhash S; Chaurawal N; Raza K
    Methods Mol Biol; 2024; 2761():457-475. PubMed ID: 38427255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
    Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X
    Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darunavir-Loaded Lipid Nanoparticles for Targeting to HIV Reservoirs.
    Desai J; Thakkar H
    AAPS PharmSciTech; 2018 Feb; 19(2):648-660. PubMed ID: 28948564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
    Wang W; Chen L; Huang X; Shao A
    AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing biopharmaceutical attributes of phospholipid complex-loaded nanostructured lipidic carriers of mangiferin: Systematic development, characterization and evaluation.
    Khurana RK; Bansal AK; Beg S; Burrow AJ; Katare OP; Singh KK; Singh B
    Int J Pharm; 2017 Feb; 518(1-2):289-306. PubMed ID: 28025072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): An improved dermatokinetic profile for inflammatory disorder(s).
    Garg NK; Sharma G; Singh B; Nirbhavane P; Tyagi RK; Shukla R; Katare OP
    Int J Pharm; 2017 Jan; 517(1-2):413-431. PubMed ID: 27956192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
    Zhou X; Zhang X; Ye Y; Zhang T; Wang H; Ma Z; Wu B
    Int J Pharm; 2015 Feb; 479(2):391-8. PubMed ID: 25556104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement.
    Khan S; Shaharyar M; Fazil M; Hassan MQ; Baboota S; Ali J
    Eur J Pharm Biopharm; 2016 Dec; 109():149-157. PubMed ID: 27793753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.